Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Shylasree, T S ^a   Bryant, Andrew ^b   Athavale, Ram ^c  

^a TATA MEMORIAL HOSPITAL   (India)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; GYNECOLOGIC SURGERY; HUMAN; MIXED MULLERIAN TUMOR; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RARE DISEASE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; FEMALE; METHODOLOGY; OVARY TUMOR;

CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; OVARIAN NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 84875520628     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006246.pub2     Document Type: Review

References (41)

1. Andersen WA. Platinum-based combination chemotherapy for malignant mixed mesodermal tumours of the ovary. Gynecologic Oncology 1989;32(3):319-22.
2. Ariyoshi K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 2000;37(5):427-36.
3. Barnholtz-Sloan JS, Morris R, Malone JM, Jr, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecologic Oncology 2004;93(2):506-12.
4. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorreli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynaecology and Obstetrics 2000;70(2):209-62.
5. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstetrics and Gynecology 1995;85(5 Pt 1):735-9.
6. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, et al.Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004;100(10):2148-53.
7. Carlson JA, Edwards C, Wharton JT, Gallager HS, Delclos L, Rutledge F. Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy. Cancer 1983;52(8):1473-7.
8. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, et al.Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Annals of Oncology 1995;6(8):755-8.
9. Chun KC, Kim JJ, Kim DY, Kim JH, Kim YM, Nam JH, et al.Optimal debulking surgery followed by placlitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecologic and Obstetric Investigation 2011;72(3):208-4.
10. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, et al.Ovarian carcinosarcomas: clinicopathological prognositc factors and evaluation of chemotherapy regimens containing platinum. Gynecologic Oncology 2008;108(1):136-40.
11. Costa MJ, Walls J. Epidermal growth factor receptor and c-erb-B-2 oncoprotein expression in female fenital tract carcinosarcomas (malignant mixed mullerian tumors) clinicopathological study of 82 cases. Cancer 1996;77:533-42.
12. National Cancer Institute: Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (http://ctep.cancer.gov/forms/CTCAEv3.pdf) August 9th 2006.
13. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds) editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
15. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecologic Oncology 2002;85(3):459-63.
16. George E, Marvivel JC, Dehner LP. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases with histogenic considerations and clinical correlation. Human Pathology 1991;22:215-23.
17. Guarino M, Giordano F, Palloti F, Polizzotti G, Tricomi P, et al.Malignant mixed mullerian tumor of the uterus, features favoring its origin from a common clone and epithelial-to-mesenchymal transformation mechanism of histogenesis. International Journal of Gynecological 2003;22:368-73.
18. Hanjani P, Petersen RO, Lipton SE, Nolte SA. Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature. Obstetrics and Gynecological Surveys 1983;38(9):537-45.
19. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, et al.Carcinosarcoma of the ovary. British Journal of Cancer 2003;88(5):654-7.
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Jin Z, Ogata S, Tamura G Katayama Y, Fukase M, Yajima M, et al.Carcinosarcomas (malignant mullerian mixed tumors of the uterus and ovary; a genetic study with special reference to histogenesis. International Journal of Gynecological Pathology 2003;22:368-73.
23. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, et al.Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecologic Oncology 2006;100:561-4.
24. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecologic Oncology 2007;105(3):657-61.
25. Morrow CP, Bundy BN, Hoffman J, Sutton G, Homesley H, et al.Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. American Journal of Clinical Oncology 1986;9:24-6.
26. Muntz HG, Jones MA, Goff BA, Fuller AF Jr, Nikrui N, Rice LW, et al.Malignant mixed mullerian tumours of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer 1995;76(7):1209-13.
27. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
28. Prendiville J, Murphy D, Renninson J, Buckley H, Crowther D. Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital. International Journal of Gynecological Cancer 1994;4(3):200-5.
29. Raji R, Guzzo F, L, Varughese J, Cocco E, Bellone S, et al.Uterine and ovarian carcinosarcomas over expressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal of Experimental & Clinical Cancer Research 2011;30(1):106.
30. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO. Carcinosarcoma of the ovary: a case-control study. Gynecologic Oncology 2011;121:477-81.
31. Russell PB, Solomon HJ. Malignant mullerian and miscellaneous mesenchymal tumors of ovary ('ovarian sarcomas'). In: Coppleson M editor(s). Gynecologic Oncology. 2nd Edition. Churchill Livingstone, 1992:971-86.
32. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al.Carcinosarcoma of the ovary - a case series. Gynecologic Oncology 2006;100(1):128-32.
33. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al.Different expression patterns of KIT, EGFR and HER-2 (c-erb-b-2) oncoprotein between epithelial and mesenchymal components of uterine carcinosarcoma. Cancer Science 2003;94:986-91.
34. Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas- a CGH and FISH study. Virchows Archiv 2008;452(3):259-68.
35. Signorelli M, Chiappa V, Minig L, Fruscio R, Perego P, Caspani G, et al.Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. International Journal of Gynecological Cancer 2009;19(6):1142-6.
36. Simon SR, Wang SE, Uhl M, Shackney S. Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecologic Oncology 1991;41(2):161-6.
37. Sonoda Y, Saigo PE, Gederici MG, Boyd J. Carcinosarcoma of the ovary in a patient with germline BRCA2 mutation: evidence for monoclonal origin. Gynecologic Oncology 2000;76:226-9.
38. Sutton GP, Blessing JA, Homesley HD, Malfetano JH. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors tumours of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecologic Oncology 1994;53:24-6.
39. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecologic Oncology 2004;93(2):336-9.
40. Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecologic Oncology 1989;32(2):228-32.
41. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.